Skip to main content

Table 3 Response to treatment by treatment response score subgroups in the three clinical trials

From: Defining responders to therapies by a statistical modeling approach applied to randomized clinical trial data

Trial Score group Number of patients (%) Cumulative probability of 2-year EDSS progression Treatment effect
  Total Placebo Laquinimod Placebo Laquinimod HR (95% CI) p*
ALLEGRO
N = 1101
NR 426 (38.7) 219 (51.4) 207 (48.6) 6.30 8.87 1.31 (0.77–2.25) 0.0007
R 675 (61.3) 336 (49.8) 339 (50.2) 10.74 4.03 0.38 (0.23–0.62)
BRAVO
N = 881
NR 367 (41.7) 181 (49.3) 186 (50.7) 7.09 8.81 1.24 (0.70–2.19) 0.006
R 514 (58.3) 268 (52.1) 246 (47.9) 9.12 3.65 0.40 (0.22–0.73)
CONCERTO
N = 1456
NR 1015 (69.7) 526 (51.8) 489 (48.2) 6.09 6.56 1.08 (0.74–1.58) 0.033
R 441 (30.3) 211 (47.8) 230 (52.2) 5.62 2.47 0.44 (0.21–0.94)
  1. Score group: NR non-responders (patients with a response score > − 0.31), R responders (patients with a response score ≤ − 0.31)
  2. EDSS Expanded Disability Status Scale, HR hazard ratio, CI confidence interval
  3. *p for treatment by score interaction